Paper Details

  1. Home
  2. Paper Details

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Author: , AfdhalNezam, AroraSanjeev, Di BisceglieAdrian M, Dvory-SobolHadas, GhalibReem, GitlinNorman, GordonStuart C, HerringRobert, KwoPaul, LalezariJacob, LawitzEric, McHutchisonJohn G, MuirAndrew J, NahassRonald, NelsonDavid R, PangPhillip S, PockrosPaul J, ReddyK Rajender, SchiffEugene, SubramanianG Mani, SulkowskiMark, SymondsWilliam T, YangJenny C, YounesZiad H, ZhuYanni

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A phase 3, randomized, open-label study of 440 patients with HCV genotype 1 infection who had not had a sustained virologic response to prior interferon-based treatment found that treatment with a once-daily, single-tablet regimen of ledipasvir and sofosbuvir resulted in high rates of sustained virologic response. The sustained virologic response rates were 94% for 12 weeks of ledipasvir-sofosbuvir, 96% for 12 weeks of ledipasvir-sofosbuvir and ribavirin, 99% for 24 weeks of ledipasvir-sofosbuvir, and 99% for 24 weeks of ledipasvir-sofosbuvir and ribavirin. No patients discontinued treatment due to adverse events.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Effective treatment for hepatitis C virus (HCV) genotype 1 infection in patients who have not had a sustained virologic response to prior interferon-based therapy represents an unmet medical need. METHODS: We conducted a phase 3, randomized, open-label study involving patients infected ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa1316366

データ提供：米国国立医学図書館（NLM）

Ledipasvir and Sofosbuvir: A Game Changer for HCV Genotype 1

The field of [Hepatitis C Virus (HCV) Treatment] is constantly seeking new solutions for patients who have not responded well to prior therapies. This study explores the effectiveness of [ledipasvir and sofosbuvir] in treating [previously treated HCV genotype 1 infection]. The researchers found that [ledipasvir and sofosbuvir] achieved high rates of [sustained virologic response (SVR)] in patients who had not achieved [SVR] with prior interferon-based treatment. This finding offers a new hope for individuals struggling with [HCV genotype 1 infection].

Ledipasvir and Sofosbuvir: A Powerful Duo for HCV Genotype 1

The study demonstrates the remarkable effectiveness of [ledipasvir and sofosbuvir] in achieving [SVR] for [HCV genotype 1 infection]. The researchers found that [SVR rates] were significantly higher in all treatment groups receiving [ledipasvir and sofosbuvir] compared to those who did not. This groundbreaking discovery could revolutionize treatment options for [HCV genotype 1 infection]. Imagine a caravan of explorers encountering a vast desert with limited resources. The arrival of [ledipasvir and sofosbuvir] is like discovering a hidden oasis, offering a vital source of relief and hope.

Ledipasvir and Sofosbuvir: A New Era in HCV Treatment

This research provides a promising avenue for treating [HCV genotype 1 infection], potentially leading to a cure for many. The high [SVR rates] achieved with [ledipasvir and sofosbuvir] mark a significant advancement in the fight against this challenging viral infection.

Dr. Camel's Conclusion

This study highlights the significant efficacy of [ledipasvir and sofosbuvir] in achieving [sustained virologic response (SVR)] for [previously treated HCV genotype 1 infection]. This groundbreaking discovery offers a new hope for individuals struggling with [HCV genotype 1 infection].

Date :
  1. Date Completed 2014-05-06
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

24725238

DOI: Digital Object Identifier

10.1056/NEJMoa1316366

Related Literature

Article Analysis
・Effective treatment of hepatitis c
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.